According to Securities Star News, as of the close of trading on May 17, 2024, Yuandong Biology (688513) closed at 58.02 yuan, down 0.99%, with a turnover rate of 0.31%, a volume of 3767.0 lots and a turnover of 21.8959 million yuan.
In terms of capital flow data on May 17, the net outflow of main funds was 250,300 yuan, accounting for 1.14% of the total turnover, the net inflow of floating funds was 1.7969 million yuan, accounting for 8.21% of the total turnover, and the net outflow of retail funds was 1.5465 million yuan, accounting for 7.06% of the total turnover.
The list of capital flows in the past 5 days is shown in the following table:
According to the financing information of Yuandong Biology, in terms of financing, the financing purchase on the same day was 844,400 yuan, the financing repayment was 1.3941 million yuan, and the net financing repayment was 549,600 yuan. In terms of securities lending, 0.0 shares were sold by securities borrowing, 0.0 shares were repaid by securities borrowing, 0.0 shares were borrowed and borrowed, and the balance of securities borrowing and lending was 0.0 million yuan. The balance of margin financing and securities lending was 46.8892 million yuan. See the following table for a list of margin trading data in the past 5 days:
The main indicators and industry rankings of the stock are as follows:
According to the first quarter report of Yuandong Biotechnology in 2024, the company's main revenue was 315 million yuan, an increase of 13.37% year-on-year; the net profit attributable to the parent company was 75.0101 million yuan, an increase of 23.0% year-on-year; deducted non-net profit of 52.0919 million yuan, an increase of 12.44% year-on-year; The debt ratio was 22.17%, the investment income was 3.1335 million yuan, the financial expenses were -944,600 yuan, and the gross profit margin was 79.82%. Yuandong Biology (688513) main business: Yuandong Biology is a high-tech enterprise driven by R&D and innovation, integrating the whole industry chain of R&D, production and sales of chemical APIs, high-end chemicals and biological drugs. The company adheres to the mission of "patient-centered, bathing in the sunshine for human health", relying on continuous technological innovation, and gradually establishes a domestic leading R&D technology and industrialization platform that meets international standards, intensively deploys the field of anesthesia and analgesia, and at the same time takes into account the rapid development of large varieties of market fields such as diabetes, cardiovascular, and anti-tumor, accelerates the R&D and industrialization of small molecule entities and biological drugs, and quickly meets the unmet clinical needs at home and abroad.
A total of 8 institutions have rated the stock in the last 90 days, 3 have given buy ratings and 5 have overweight ratings. The average institutional price target over the last 90 days is 75.1.
Explanation of the term capital flow: It refers to the reversal of the flow of funds through price changes. When the stock price is rising, the turnover generated by the active buy order is the force that drives the stock price up, which is defined as the inflow of funds, and the turnover generated by the active sell order when the stock price is in a falling state is the force that pushes the stock price down, and this part of the turnover is defined as the outflow of funds. The difference between the two on the day is the net force that is left to push the stock price up after the two forces offset on that day. The main capital flow, floating capital flow and retail capital flow are calculated by the transaction amount of each transaction order.
Note: The main funds are extra-large single transactions, the floating capital is large single transactions, and the retail investors are small and medium-sized single transactions
The above content is compiled by Securities Star based on public information, generated by an algorithm (Network Information Calculation No. 310104345710301240019), and has nothing to do with the position of this site, if there is a problem with the data, please contact us. This article is a compilation of data and does not constitute any investment advice for you, investment is risky, please make a cautious decision.